Medical Devices News and Research

RSS

InfraReDx to present LipiScan scientific abstracts at AHA 2010

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced the upcoming presentation of three LipiScan-related scientific abstracts at the American Heart Association Scientific Sessions 2010 (AHA 2010), being held Nov. 13-17, 2010 at McCormick Place in Chicago.

15 Nov 2010

New therapeutic implant synchronizes fading heart beat

One of the largest, most extensive worldwide investigations into heart failure, led by the University of Ottawa Heart Institute (UOHI), conclusively proves that a new therapeutic implant synchronizes and strengthens a fading heart beat while reducing risk of death by 24% compared to the current treatment.

14 Nov 2010

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2010.

12 Nov 2010

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.

12 Nov 2010

NaturalNano's HNT can improve separation of CTCs from blood

NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.

12 Nov 2010

Comparative effectiveness push tailed by controversy, distrust

Two-third of Americans agree that studies comparing treatments are needed, but even more 75 percent say the government and insurers would use the results of such studies to ration medical care, MarketWatch reports.

12 Nov 2010

SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors

Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.

11 Nov 2010

Bay Area health care start-up investments down 35% in third quarter

In California's Bay Area, third-quarter venture capital investment in health care-related companies totaled $421.5 million, down 35 percent from $650.6 million in the same period a year earlier, according to research firm VentureSource.

11 Nov 2010

Ky. Health Plan audit; employee costs in Massachusetts; state reform implementation politics

An organization that manages taxpayer-funded health services for Kentucky's poor and disabled spent freely on luxury hotels, meals, salaries, lobbying and consulting, a state auditor found in a 200-plus-page report which calls for stricter accountability for Passport Health Plan, a Medicaid managed-care provider that serves 164,000 people in Louisville and more than a dozen nearby counties.

10 Nov 2010

Health reform policy: Flexible spending, device taxes and waivers

One health law provision will be a bummer for people who use the tax-free dollars stored in flexible spending accounts, Kaiser Health News reports. "Starting in January, you'll no longer be able to use your FSA for over-the-counter drugs and medicines unless you have a doctor's prescription. Experts agree that the new rules will likely discourage people from tapping their FSAs for routine purchases of aspirin, vitamins, cough medicine and other drugstore essentials" (Andrews, 11/8).

10 Nov 2010

Baxa launches ExactaMix 1200 Automated Compounding Device

Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.

9 Nov 2010

Covidien fourth quarter net sales increase 3% to $2.67 billion

Covidien plc today reported results for the fourth quarter of fiscal 2010 (July - September 2010). Fourth-quarter net sales of $2.67 billion increased 3% from the $2.59 billion reported a year ago, with foreign exchange rate movement reducing the quarterly sales growth rate by approximately one percentage point.

9 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

In a letter addressed to Dr. Harold E. Varmus, director of the NCI, and Dr. Margaret Hamburg, FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc., requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. Erickson stated: "The NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing."

9 Nov 2010

CorMatrix receives $2.3 million grants under QTDP program to advance ECM technology

CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, today announced that the Company has been awarded $2.3 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of their unique ECM technology.

9 Nov 2010

TechniScan restructures convertible debt

TechniScan, Inc. a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced a restructuring of its convertible debt.

8 Nov 2010

CardioNet to acquire Biotel

CardioNet, Inc., a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that the Company entered into a definitive merger agreement with Biotel, Inc. to acquire all of the outstanding shares of Biotel for $11 million, or $3.84 per share, before adjustments for working capital. In connection with the merger agreement, the parties entered into a settlement agreement to dismiss the outstanding litigation between them, which will be effective as of the close of the merger.

8 Nov 2010

Chindex 2011 second quarter revenue increases 18.6% to $45.2 million

Chindex International, Inc. a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the second quarter and first half of fiscal year 2011, which ended September 30, 2010.

8 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

FDA announces reclassification for Full Field Digital Mammography Systems

The U.S. Food and Drug Administration today announced that it is easing the pathway to market for mammography systems that produce computerized X-ray images of the entire breast.

8 Nov 2010